Login

Financial Snapshot

Revenue
TTM
$127.5M
Gross Margin
TTM
77.07%
Net Income
TTM
-$46.64M
Current Assets
2026 Q1
Current Liabilities
2026 Q1
Current Ratio
2026 Q1
1019.96%
Total Assets
2026 Q1
Total Liabilities
2026 Q1
Book Value
2026 Q1
267.3M
Cash
2026 Q1
P/E
Last 4 Quarters
N/A
Free Cash Flow
TTM
-$21.59M

Stock Price

Loading...
Market Cap: $204.5 Million

About Rxsight Inc

RxSight Inc (NASDAQ: RXST) is a medical device company focused on the treatment of cataracts through a proprietary adjustable intraocular lens system. The company makes money by selling its Light Adjustable Lens (LAL) and the associated Light Delivery Device (LDD) used to customize vision after cataract surgery. The LAL system allows post-surgical adjustment of a patient's vision correction using ultraviolet light, differentiating it from fixed intraocular lenses implanted by competitors. RxSight sells its products to ophthalmologists and cataract surgery centers, primarily in the United States. The filing was made on 2026-02-25 covering the fiscal year ended in that period. Due to limited financial detail in the available filing excerpts, specific revenue figures, segment breakdowns, customer counts, and named competitors cannot be confirmed from this source and are omitted accordingly.

Revenue model
Product sales of the Light Adjustable Lens (LAL) and Light Delivery Device (LDD) to ophthalmic surgery providers. Based on available excerpts, specific pricing, subscription, or recurring revenue details cannot be confirmed.
Products and services
Light Adjustable Lens (LAL), a post-surgically adjustable intraocular lens; Light Delivery Device (LDD), the ultraviolet light instrument used to perform vision adjustments after LAL implantation.
Customers and end markets
Ophthalmologists and cataract surgery centers. End market is cataract surgery patients seeking customized vision correction. Specific customer concentration data not supported by available excerpts.
Value-chain role
Medical device manufacturer and direct seller of an intraocular lens system used in cataract surgery procedures.
Geographic exposure
Primarily United States, based on filing registration details. International exposure not confirmed by available excerpts.

Source: SEC 10-K, filed 2026-02-25

Industry: Ophthalmic Goods Peers: Bioventus Inc CERUS CORP Sanara Medtech Inc OraSure Technologies Inc Pulmonx Corp VolitionRX Ltd SmileDirectClub, Inc. TELA Bio Inc Utah Medical Products Inc

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support